BACKGROUND: The purpose of this study was to describe the expression patterns of transforming growth factor (TGF)-beta(1) and its receptors in transitional cell carcinoma (TCC) of the bladder, to investigate the relation between the TGF-beta(1) and its receptors, and to determine whether altered expression of TGF-beta or its receptors is associated with disease progression and survival in patients with TCC of the bladder. METHODS: Immunohistochemical staining for TGF-beta(1) and its receptors I and II was conducted on formalin fixed paraffin embedded archival cystectomy specimens of 80 patients with bladder TCC. Immunoreactivity was categorized as either positive or negative in a blinded fashion. RESULTS: Expression of TGF-beta(1), TGF-beta-RI, and TGF-beta-RII was altered in 51 (64%), 34 (43%), and 38 (48%) specimens, respectively. Sixty (75%) specimens had altered expression of at least 1 of the 3 TGF-betas, and 26 (33%) had altered expression of all 3. Expression of the three TGF-betas was highly concordant (P < 0.018). Loss of expression of TGF-beta-RI or TGF-beta-RII was associated with invasive tumor stage (P < 0.001), high grade (P < 0.006), and lymphovascular invasion (P < 0.030). Overexpression of TGF-beta(1) was associated with invasive tumor stage only (P = 0.024). With a median follow-up of 101 months, TGF-beta-RI was an independent predictor of both disease progression (P = 0.007) and disease specific survival (P = 0.006) whereas TGF-beta(1) was an independent predictor of disease progression only (P = 0.050). Transforming growth factor-beta-RII was not independently associated with either disease progression or survival. CONCLUSIONS: Altered expression of TGF-beta(1) and its receptors is common in TCC of the bladder. Overexpression of TGF-beta(1) is associated with the loss of expression of its receptors. Transforming growth factor-beta(1) and TGF-beta-RI are independently associated with clinical outcome in patients with bladder TCC treated by radical cystectomy. Copyright 2001 American Cancer Society.
BACKGROUND: The purpose of this study was to describe the expression patterns of transforming growth factor (TGF)-beta(1) and its receptors in transitional cell carcinoma (TCC) of the bladder, to investigate the relation between the TGF-beta(1) and its receptors, and to determine whether altered expression of TGF-beta or its receptors is associated with disease progression and survival in patients with TCC of the bladder. METHODS: Immunohistochemical staining for TGF-beta(1) and its receptors I and II was conducted on formalin fixed paraffin embedded archival cystectomy specimens of 80 patients with bladder TCC. Immunoreactivity was categorized as either positive or negative in a blinded fashion. RESULTS: Expression of TGF-beta(1), TGF-beta-RI, and TGF-beta-RII was altered in 51 (64%), 34 (43%), and 38 (48%) specimens, respectively. Sixty (75%) specimens had altered expression of at least 1 of the 3 TGF-betas, and 26 (33%) had altered expression of all 3. Expression of the three TGF-betas was highly concordant (P < 0.018). Loss of expression of TGF-beta-RI or TGF-beta-RII was associated with invasive tumor stage (P < 0.001), high grade (P < 0.006), and lymphovascular invasion (P < 0.030). Overexpression of TGF-beta(1) was associated with invasive tumor stage only (P = 0.024). With a median follow-up of 101 months, TGF-beta-RI was an independent predictor of both disease progression (P = 0.007) and disease specific survival (P = 0.006) whereas TGF-beta(1) was an independent predictor of disease progression only (P = 0.050). Transforming growth factor-beta-RII was not independently associated with either disease progression or survival. CONCLUSIONS: Altered expression of TGF-beta(1) and its receptors is common in TCC of the bladder. Overexpression of TGF-beta(1) is associated with the loss of expression of its receptors. Transforming growth factor-beta(1) and TGF-beta-RI are independently associated with clinical outcome in patients with bladder TCC treated by radical cystectomy. Copyright 2001 American Cancer Society.
Authors: Michael Rink; Eugene K Cha; David Green; Jens Hansen; Brian D Robinson; Yair Lotan; Arthur I Sagalowsky; Felix K Chun; Pierre I Karakiewicz; Margit Fisch; Douglas S Scherr; Shahrokh F Shariat Journal: Curr Urol Rep Date: 2012-04 Impact factor: 3.092
Authors: N E El-Bassiouni; M M F Nosseir; M E Madkour; M M K Zoheiry; I W Bekheit; R A Ibrahim; I M Ibrahim; A E El Bassiouny Journal: Mol Biol Rep Date: 2012-02-09 Impact factor: 2.316
Authors: Sounak Gupta; Andrew M Hau; Hikmat A Al-Ahmadie; Jyoti Harwalkar; Aaron C Shoskes; Paul Elson; Jordan R Beach; George S Hussey; William P Schiemann; Thomas T Egelhoff; Philip H Howe; Donna E Hansel Journal: Am J Pathol Date: 2016-03-14 Impact factor: 4.307
Authors: Bérengère Salomé; John P Sfakianos; Daniel Ranti; Jorge Daza; Christine Bieber; Andrew Charap; Christian Hammer; Romain Banchereau; Adam M Farkas; Dan Fu Ruan; Sudeh Izadmehr; Daniel Geanon; Geoffrey Kelly; Ronaldo M de Real; Brian Lee; Kristin G Beaumont; Sanjana Shroff; Yuanshuo A Wang; Ying-Chih Wang; Tin Htwe Thin; Monica Garcia-Barros; Everardo Hegewisch-Solloa; Emily M Mace; Li Wang; Timothy O'Donnell; Diego Chowell; Ruben Fernandez-Rodriguez; Mihaela Skobe; Nicole Taylor; Seunghee Kim-Schulze; Robert P Sebra; Doug Palmer; Eleanor Clancy-Thompson; Scott Hammond; Alice O Kamphorst; Karl-Johan Malmberg; Emanuela Marcenaro; Pedro Romero; Rachel Brody; Mathias Viard; Yuko Yuki; Maureen Martin; Mary Carrington; Reza Mehrazin; Peter Wiklund; Ira Mellman; Sanjeev Mariathasan; Jun Zhu; Matthew D Galsky; Nina Bhardwaj; Amir Horowitz Journal: Cancer Cell Date: 2022-09-12 Impact factor: 38.585
Authors: Azza E I El-Bassiouny; Mona M K Zoheiry; Mona M F Nosseir; Eman G El-Ahwany; Raafat A Ibrahim; Nora E I El-Bassiouni Journal: MedGenMed Date: 2007-08-28
Authors: Italia Grenga; Renee N Donahue; Morgan L Gargulak; Lauren M Lepone; Mario Roselli; Marijo Bilusic; Jeffrey Schlom Journal: Urol Oncol Date: 2017-11-02 Impact factor: 3.498
Authors: Mikhail G Dozmorov; Kimberly D Kyker; Ricardo Saban; Nicholas Knowlton; Igor Dozmorov; Michael B Centola; Robert E Hurst Journal: BMC Cancer Date: 2006-01-13 Impact factor: 4.430